Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY (ANTEY)

National Research Center for Preventive Medicine

Status: Completed

Conditions: Atrial Fibrillation

Study type: Observational

Funder types: Other

Identifiers

NCT03790917

ANTEY

Details and patient eligibility

About

A prospective non-interventional single-centre study aimed to evaluate actual adherence of AF patients using the validated adherence Scale.

Primary Study Objective(s) Primary study objective The aim of the present study is to assess adherence to therapy and factors associated with adherence in patients with CV disease complicated by non-valvular atrial fibrillation requiring OAC treatment within the outpatient registry PROFILE (prospective, observational study).

1. Data collection in patients with non-valvular atrial fibrillation requiring OAC treatment included in the registry
2. Evaluation of actual patient adherence to OACs

Secondary Study Objective(s)

1. Evaluation of potential patient adherence to OACs
2. Determination of the most significant factors associated with adherence to OACs in patients with non-valvular AF
3. Validation of new original 5-item Questionnaire
4. Evaluation of doctor's adherence to OAC prescription according to Guidelines (ESC). Management of atrial fibrillation,2016)

Full description

AF patients from ongoing PROFILE registry will be invited to visit the scientific center.

2 visits with a 6-month interval are expected for each patient as part of routine clinical practice and phone contact is scheduled for each patient 1 year from the first visit to the scientific center (follow-up period).

Enrollment: 201 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women above 18 years of age who were included in the PROFILE registry by the start of the observational study
• Presence of written informed consent to participate in the study, fill in the study questionnaires and have personal data analyzed
• Presence of any form of non-valvular atrial fibrillation with CHA2DS2-VASc score of ≥1 or patients with CHA2DS2-VASc score = 0, who are already taking OAK

Exclusion criteria

• Patients with high bleeding risk, including patients with:

  • Congenital or acquired bleeding disorders
  • Uncontrolled resistant hypertension
  • Exacerbation of gastric and duodenal ulcer
  • Vascular retinopathy
  • Recent history of intracranial or intracerebral hemorrhage
  • Pathology of the brain and spinal cord vessels
  • Recent history of brain, spinal cord or eye surgery
  • History of bronchiectasis or pulmonary hemorrhage
  • A CHA2DS2-VASc score of 0 (OACs are not indicated)
  • Pregnancy, lactation
  • Planned surgery
  • Known hypersensitivity to ingredients of medications used in the study

Trial design